Home › Lymphoma › Texas › Houston
Pag-aaral pangklinika para sa Lymphoma sa Houston, TX
34 pag-aaral para sa Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Houston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Nagre-recruitPhase 1
- The University of Texas M D Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
Nagre-recruitPhase 2
- MD Anderson Cancer Center, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Nagre-recruitPhase 2
- MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Nagre-recruitPhase 3
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
- Texas Children's Hospital, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Nagre-recruitPhase 1
- University of Texas - MD Anderson Cancer Center, Houston
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Nagre-recruitPhase 2
- UT MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Nagre-recruitPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Nagre-recruitPhase 1/2
- Research Site, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Nagre-recruitPhase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Nagre-recruitPhase 3
- Research Site, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Nagre-recruitPhase 2
- MD Anderson Cancer Center, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Nagre-recruitPhase 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Nagre-recruitPhase 1/2
- Baylor College of Medicine, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Nagre-recruitPhase 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Nagre-recruitPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Nagre-recruitPhase 1/2
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Nagre-recruitPhase 1/2
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Nagre-recruitPhase 1
- UT MD Anderson, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Nagre-recruitPhase 2
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Nagre-recruitPhase 2
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Nagre-recruitPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Nagre-recruitPhase 1
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
Nagre-recruitPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Nagre-recruitPhase 1/2
- Dren Investigational Site, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Nagre-recruit
- MD Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Nagre-recruitObservasyonal na pag-aaral
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Nagre-recruitObservasyonal na pag-aaral
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Nagre-recruitPhase 2
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Nagre-recruitPhase 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pag-aaral para sa Lymphoma sa ibang lungsod
- Boston, MA34 pag-aaral
- New York City, NY33 pag-aaral
- Washington, DC23 pag-aaral
- Baldwin Park, CA22 pag-aaral
- Chicago, IL19 pag-aaral
- Durham, NC17 pag-aaral
- St. Louis, MO15 pag-aaral
- Cleveland, OH13 pag-aaral
- Seattle, WA13 pag-aaral
- Atlanta, GA13 pag-aaral
- Philadelphia, PA13 pag-aaral
- Edison, NJ12 pag-aaral
Iba pang pag-aaral sa Houston
- Non-Small Cell Lung Cancer143 pag-aaral
- Kanser sa Suso126 pag-aaral
- Kanser (lahat ng uri)124 pag-aaral
- Colorectal Cancer101 pag-aaral
- Metastatic Cancer100 pag-aaral
- Kanser sa Ovary90 pag-aaral
- Acute Myeloid Leukemia88 pag-aaral
- Kanser sa Baga78 pag-aaral
- Kanser sa Prostate73 pag-aaral
- Kanser ng Endometrium69 pag-aaral
- Melanoma61 pag-aaral
- Kanser sa Pancreas59 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.